Regeneron Pharmaceuticals (NASDAQ:REGN) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.
Insider & Institutional Ownership
85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of Myriad Genetics shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current recommendations and price targets for Regeneron Pharmaceuticals and Myriad Genetics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Regeneron Pharmaceuticals | 0 | 5 | 14 | 1 | 2.80 |
| Myriad Genetics | 1 | 3 | 0 | 0 | 1.75 |
Regeneron Pharmaceuticals currently has a consensus target price of $644.1739, suggesting a potential upside of 28.63%. Myriad Genetics has a consensus target price of $21.00, suggesting a potential downside of 22.02%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Regeneron Pharmaceuticals is more favorable than Myriad Genetics.
Earnings & Valuation
This table compares Regeneron Pharmaceuticals and Myriad Genetics' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Regeneron Pharmaceuticals | $7.86 billion | 6.86 | $2.12 billion | $21.47 | 23.45 |
| Myriad Genetics | $638.60 million | 3.22 | $-199,500,000.00 | ($0.35) | -78.03 |
Regeneron Pharmaceuticals has higher revenue and earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Regeneron Pharmaceuticals and Myriad Genetics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Regeneron Pharmaceuticals | 38.28% | 28.97% | 20.11% |
| Myriad Genetics | -32.49% | -4.07% | -2.68% |
Risk and Volatility
Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.
Summary
Regeneron Pharmaceuticals beats Myriad Genetics on 13 of the 15 factors compared between the two stocks.
